Biotechnology News and Research

RSS

Vitamin E can significantly reduce risk of heart attacks for diabetics with certain gene variant

Vitamin E supplements can significantly reduce the risk of heart attacks and related deaths for diabetics who carry a particular version of a gene, according to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel.

21 Nov 2007

New Zeiss microscope peers into secret lives of cells

“See those white sparks?” asks Kirk Czymmek, as he points to the video on his computer screen of a highly magnified heart cell in action.

21 Nov 2007

Report on new therapies and vaccines for HIV/AIDS

Pharmaceutical researchers are testing 92 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

21 Nov 2007

New research helps explain how tumors go undetected by the body

Scientists studying how immune cells are regulated in healthy individuals, have made a key discovery in understanding why tumours may go undetected by the immune system and remain untreated by the body's own natural defences.

19 Nov 2007

Super-tiny structures for biomedical research

The University of Massachusetts Amherst is host to a new nanomedicine institute focused on developing super-tiny structures for biomedical research.

19 Nov 2007

MIT researchers devised novel way to create tiny colonies of living human liver cells that model full-sized organs

Liver toxicity is one of the main reasons pharmaceutical companies pull drugs off the market. These dangerous drugs slip through approval processes due in part to the shortcomings of liver toxicity tests. Existing tests rely on liver cells from rats, which do not always respond to toxins the way human cells do. Or they rely on dying human cells that survive for only a few days in the lab.

19 Nov 2007

Human health, agriculture and the environment to benefit from bioengineering project at the University of Kent

Martin Warren, Professor of Biochemistry at the University of Kent’s Department of Biosciences, has been awarded over £750,000 from the Biotechnology and Biological Sciences Research Council for a study into biochemical pathways that could ultimately lead to improved health benefits for humans, as well as the development of important new technologies and products for agriculture and bioremediation (the use of plants or microorganisms to clean up pollution or contaminated material).

19 Nov 2007

Researchers identify compound that eliminates myotonia - a symptom of muscular dystrophy

Researchers at the University of Rochester Medical Center (URMC) have identified a compound that eliminates myotonia - a symptom of muscular dystrophy - in mice. The research was published online in the Journal of Clinical Investigation.

16 Nov 2007

Pfizer and Nektar resolve outstanding Exubera contractual issues

Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.

14 Nov 2007

Ageing exhibition reveals scientists' plans for lifelong health

The UK population is rapidly getting older: a predicted 1 in 4 people will be over the age of 65 by 2031. Ensuring that an increasingly ageing population stays healthy and mobile is a challenge for both the Government and the scientific research community.

13 Nov 2007

Potential block buster on the horizon - new vaccine to control high blood pressure

A vaccine that would help people control their blood pressure is showing promise in early trials.

7 Nov 2007

New liver model for drug tests

In the early stages of drug development, a drug’s effect is tested in animal experiments.

6 Nov 2007

Synthetic version of chlorotoxin shows promise in treatment of brain tumors

A drug developed and tested at UAB (University of Alabama at Birmingham) targeted at malignant brain tumors known as glioma has shown promising results in a Phase 1 trial, according to results presented at the American Society for Therapeutic Radiology and Oncology annual meeting.

6 Nov 2007

Novel approaches to hypertension control

A hypertension vaccine could be an important alternative to conventional drug therapy because of patients' inconsistent drug intake - if further research supports results from a small study testing the safety and tolerability of a vaccine.

6 Nov 2007

Genes identified to protect brassicas from damaging disease

Scientists have identified a new way to breed brassicas, which include broccoli, cabbage and oilseed rape, resistant to a damaging virus.

2 Nov 2007

Search for new uses for heroin and marijuana

The world's leading expert on the opium poppy has joined forces with researchers working on another infamous drug-producing plant – cannabis – in hopes of finding new uses for the much-maligned sources of heroin and marijuana.

1 Nov 2007

Molecular condom that protects against AIDS

Utah Gov. Jon Huntsman's ongoing trade delegation to India will initiate a long-term international collaboration with that country and the University of Utah.

31 Oct 2007

Whole parasite malaria vaccine to be manufactured for clinical trials

Sanaria Inc. and the PATH Malaria Vaccine Initiative has officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.

29 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Sigma-Aldrich and Oxford BioMedica win key ruling in Open Biosystems patent case

Sigma-Aldrich and Oxford BioMedica have announced that they received a key order confirming the strength and validity of intellectual property owned by Oxford BioMedica and licensed exclusively in the research field to Sigma-Aldrich.

25 Oct 2007